Bioterrorism. Researchers question obsession with Cipro.
Enserink
M
M
D000881:Anthrax / Q000188:drug therapy* / Q000382:microbiology; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000942:Antigens, Bacterial; D001408:Bacillus anthracis / Q000187:drug effects* / Q000235:genetics; D001427:Bacterial Toxins / Q000737:chemistry / Q000378:metabolism; D023482:Bioterrorism; D002939:Ciprofloxacin / Q000494:pharmacology / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D004363:Drug Utilization; D006801:Humans; D009154:Mutation; D011956:Receptors, Cell Surface / Q000378:metabolism; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D014481:United States; D014486:United States Food and Drug Administration
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000942:Antigens, Bacterial; D001427:Bacterial Toxins; D011956:Receptors, Cell Surface; C030325:anthrax toxin; D002939:Ciprofloxacin